Johnson & Johnson (NYSE:JNJ – Get Free Report)’s stock had its “overweight” rating reaffirmed by equities researchers at Cantor Fitzgerald in a research report issued on Monday, Benzinga reports. They presently have a $215.00 price objective on the stock. Cantor Fitzgerald’s price target indicates a potential upside of 36.23% from the stock’s previous close.
Several other equities analysts also recently issued reports on the stock. StockNews.com raised shares of Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a report on Friday, September 29th. Morgan Stanley cut their price objective on shares of Johnson & Johnson from $187.00 to $172.00 and set an “equal weight” rating for the company in a research report on Thursday, August 31st. Royal Bank of Canada started coverage on Johnson & Johnson in a research note on Wednesday, October 4th. They issued an “outperform” rating and a $178.00 price target on the stock. Barclays cut their target price on Johnson & Johnson from $175.00 to $158.00 and set an “equal weight” rating on the stock in a research report on Friday, September 8th. Finally, HSBC initiated coverage on shares of Johnson & Johnson in a research note on Wednesday, September 6th. They set a “hold” rating and a $175.00 target price on the stock. Nine analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $171.06.
Johnson & Johnson Price Performance
JNJ stock traded up $0.18 during trading on Monday, hitting $157.82. 1,523,855 shares of the company’s stock traded hands, compared to its average volume of 12,435,688. The business has a fifty day simple moving average of $164.30 and a 200 day simple moving average of $162.40. Johnson & Johnson has a 52 week low of $150.11 and a 52 week high of $181.04. The company has a debt-to-equity ratio of 0.44, a quick ratio of 0.88 and a current ratio of 1.12. The stock has a market capitalization of $410.17 billion, a price-to-earnings ratio of 31.92, a P/E/G ratio of 3.19 and a beta of 0.55.
Johnson & Johnson (NYSE:JNJ – Get Free Report) last announced its quarterly earnings data on Thursday, July 20th. The company reported $2.80 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.62 by $0.18. Johnson & Johnson had a net margin of 13.35% and a return on equity of 36.72%. The business had revenue of $25.53 billion during the quarter, compared to the consensus estimate of $24.63 billion. During the same quarter last year, the firm earned $2.59 earnings per share. The firm’s quarterly revenue was up 6.3% compared to the same quarter last year. As a group, research analysts expect that Johnson & Johnson will post 10.02 EPS for the current fiscal year.
Insiders Place Their Bets
In related news, VP Peter Fasolo sold 20,000 shares of the company’s stock in a transaction on Tuesday, July 25th. The stock was sold at an average price of $170.32, for a total transaction of $3,406,400.00. Following the transaction, the vice president now directly owns 102,696 shares of the company’s stock, valued at $17,491,182.72. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. In other news, VP Peter Fasolo sold 20,000 shares of Johnson & Johnson stock in a transaction dated Tuesday, July 25th. The stock was sold at an average price of $170.32, for a total value of $3,406,400.00. Following the transaction, the vice president now directly owns 102,696 shares in the company, valued at $17,491,182.72. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider William Hait sold 14,698 shares of the company’s stock in a transaction on Wednesday, July 26th. The shares were sold at an average price of $172.00, for a total transaction of $2,528,056.00. Following the transaction, the insider now owns 87,747 shares of the company’s stock, valued at $15,092,484. The disclosure for this sale can be found here. 0.20% of the stock is owned by company insiders.
Institutional Inflows and Outflows
Several institutional investors have recently bought and sold shares of JNJ. DORCHESTER WEALTH MANAGEMENT Co lifted its holdings in Johnson & Johnson by 8.6% during the 1st quarter. DORCHESTER WEALTH MANAGEMENT Co now owns 67,618 shares of the company’s stock valued at $14,975,000 after purchasing an additional 5,327 shares during the last quarter. Cantor Fitzgerald Investment Advisor L.P raised its holdings in Johnson & Johnson by 88.9% in the 1st quarter. Cantor Fitzgerald Investment Advisor L.P now owns 175,194 shares of the company’s stock valued at $31,049,000 after acquiring an additional 82,429 shares during the period. AMI Investment Management Inc. increased its stake in shares of Johnson & Johnson by 8.8% during the first quarter. AMI Investment Management Inc. now owns 18,305 shares of the company’s stock worth $3,244,000 after purchasing an additional 1,475 shares during the period. Equitable Holdings Inc. lifted its holdings in Johnson & Johnson by 4.9% during the 1st quarter. Equitable Holdings Inc. now owns 45,673 shares of the company’s stock worth $8,095,000 after purchasing an additional 2,119 shares during the last quarter. Finally, USS Investment Management Ltd boosted its stake in Johnson & Johnson by 2.4% in the 1st quarter. USS Investment Management Ltd now owns 860,371 shares of the company’s stock valued at $152,488,000 after purchasing an additional 20,528 shares during the period. Institutional investors own 68.40% of the company’s stock.
About Johnson & Johnson
Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company’s Consumer Health segment provides skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; baby care products under the JOHNSON’S and AVEENO Baby brands; oral care products under the LISTERINE brand; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products.